BPC-157 is not FDA-approved , and its use may be considered off-label
The dosing framework comes from extrapolation: murine studies scaled by body surface area, in vitro keratinocyte studies reverse-engineered to estimate required serum concentration, and anecdotal protocols from research communities using off-label peptides
35 Teunisse, S., Bollen, A
Drug interactions and safety considerations The semaglutide glycine B12 blend interacts with medications and supplements in ways that patients must understand before starting treatment
These include: Neurological symptoms : tingling or numbness in hands and feet (peripheral neuropathy), difficulty walking or balance problems, memory difficulties, or mood changes including depression Haematological signs : persistent fatigue, weakness, pale or jaundiced skin, or shortness of breath Glossitis : a sore, red, smooth tongue Cognitive symptoms : difficulty concentrating, confusion, or "brain fog" Seek urgent medical attention if you experience rapidly worsening neurological symptoms, significant difficulty walking, severe paraesthesia, or marked cognitive decline, as these may require immediate assessment
